Short Interest in Ikena Oncology, Inc. (NASDAQ:IKNA) Grows By 9.7%

Ikena Oncology, Inc. (NASDAQ:IKNA) saw a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 90,600 shares, a growth of 9.7% from the November 15th total of 82,600 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average trading volume of 58,300 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Trading of Ikena Oncology

Several institutional investors and hedge funds have recently modified their holdings of IKNA. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Ikena Oncology in the 2nd quarter valued at approximately $30,000. BBR Partners LLC bought a new position in shares of Ikena Oncology in the 2nd quarter valued at approximately $33,000. AQR Capital Management LLC bought a new stake in shares of Ikena Oncology in the 2nd quarter worth approximately $36,000. FMR LLC raised its stake in shares of Ikena Oncology by 94.1% in the third quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after acquiring an additional 18,607 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Ikena Oncology in the 2nd quarter valued at $75,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $4.00 target price on shares of Ikena Oncology in a research note on Monday, November 11th. Wedbush restated a “neutral” rating and set a $2.00 target price on shares of Ikena Oncology in a research note on Thursday, November 7th.

Ikena Oncology Stock Down 0.6 %

Shares of NASDAQ:IKNA traded down $0.01 during midday trading on Friday, reaching $1.65. The company’s stock had a trading volume of 79,810 shares, compared to its average volume of 231,428. Ikena Oncology has a twelve month low of $1.22 and a twelve month high of $2.32. The firm has a market capitalization of $79.63 million, a PE ratio of -1.34 and a beta of 0.49. The stock has a fifty day moving average of $1.71 and a 200 day moving average of $1.70.

Ikena Oncology (NASDAQ:IKNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.08. Sell-side analysts anticipate that Ikena Oncology will post -0.91 earnings per share for the current fiscal year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.